Name | Type | Posted | Actions |
|---|---|---|---|
Amendment_5to_the_RFP_-_10-18-2024_0005.pdf | Oct 18, 2024 | ||
Amendment_4_to_the_RFP_-_10-11-2024_0004.pdf | Oct 11, 2024 | ||
Amendment_3_to_the_RFP_-_10-08-2024_0003.pdf | Oct 8, 2024 | ||
Amendment_2_to_the_RFP_-_9-20-24_0002.pdf | Sep 20, 2024 | ||
Amendment_1_to_RFP_75N94024R00008_9-11-24_0001.pdf | Sep 11, 2024 | ||
Sol_75N94024R00008.pdf | Sep 4, 2024 |
A--BPCA Pediatric Trials Network
Contact and place of performance
OSINSKI, ELIZABETH J
Not specified
Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN)
The National Institutes of Health, specifically the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has issued solicitation 75N94024R00008 to support the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN). This initiative focuses on conducting research and clinical trials to improve pediatric drug labeling and ensure the safety and efficacy of pharmaceuticals used in children. The procurement is classified under NAICS code 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN11 for Health R&D Services; Health Care Services; Basic Research.
This requirement is published as a full and open competition with a response deadline of November 4, 2024. Elizabeth J. Osinski serves as the primary point of contact for the solicitation, which includes the original RFP and five subsequent amendments released between September 11 and October 18, 2024. These documents provide the formal framework for the network's operations and the submission requirements for interested parties.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.